OPENAI AND FDA DISCUSS AI IN DRUG EVALUATION

Summary from the TLDR AI newsletter

OpenAI and the FDA held meetings to explore how AI could expedite drug approvals, signaling a shift toward modernizing regulatory science with machine learning.